Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varlilumab and Nivolumab in Advanced Refractory Solid Tumors
NCT02335918Phase 2Completed
- Sponsor
- Celldex Therapeutics
- Start
- Jan 2015
- Primary completion
- Dec 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of varlilumab in squamous cell carcinoma of the head and neck (HNSCC), ovarian carcinoma, colorectal cancer (CRC), renal cell carcinoma (RCC), glioblastoma (GBM), sponsored by Celldex Therapeutics. Started Jan 2015; status: completed.
02
Drugs
varlilumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)ovarian carcinomacolorectal cancer (CRC)renal cell carcinoma (RCC)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02335918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02335918.